Research and Markets: Portugal Pharmaceuticals and Healthcare Market is Forecast to Reach Us$5.42Bn by 2013

DUBLIN--(Business Wire)--
Research and Markets
(http://www.researchandmarkets.com/research/bf05b8/portugal_pharmaceu) has
announced the addition of the "Portugal Pharmaceuticals and Healthcare Report Q2
2009" report to their offering.

Portugal Pharmaceuticals and Healthcare Report provides independent forecasts
and competitive intelligence on Portugal's pharmaceuticals and healthcare
industry.

The Portugal Pharmaceuticals & Healthcare Report Q2 2009 is the latest addition
to our Industry Survey & Forecasts Series. The value of the country's
pharmaceutical market is forecast to reach US$5.42bn by 2013, representing a
compound annual growth rate (CAGR) of 1.34%. However, this top line projection
ignored that fact that we are expecting a contraction in market size in 2009,
followed by expansion in the subsequent years. Combined sales of generic drugs,
patented products and over-the counter (OTC) medicines were calculated to be
US$5.07bn in 2008.

While Portugal takes 9th and last place in our Western Europe Pharmaceutical
Business Environment Rankings for Q209, it must be remembered that the country
is still the 17th most attractive pharmaceutical market in global terms. Over
the next five years, we expect Portugal to fall down the world ranking, as large
high-growth emerging markets - such as Brazil and China - become more alluring
to multinational drug makers.

Prices of pharmaceuticals in Portugal - both patented and generic - are among
the highest in the European Union (EU). To rectify this situation and ultimately
benefit patients, the government amended Decree Law 65/2007 in the third quarter
of 2008. The price of generic drugs became 30% lower, which impelled originator
brands to implement a similar cut. Unlike other European countries, generic
medicines in Portugal take a greater share of the market in value terms than
they do in volume.

The Burden of Disease Database (BoDD) reveals that Portugal will become a
healthier country over the next twenty years. The number of disability-adjusted
life years (DALYs) lost to all disease will decrease from 3,244,814 in 2008 to
2,982,339 in 2030, a drop of nearly 10%. As is the norm for developed states,
the burden of communicable disease will fall faster than that of
non-communicable disease. The three main factors behind this projected drop in
disease burden is greater access to healthcare, earlier diagnoses of medical
conditions and increasing usage of pharmaceuticals.

Key Topics Covered:

* Executive Summary
* Portugal Pharmaceuticals And Healthcare Industry SWOT
* Pharmaceutical Business Environment Ratings
* Limits To Potential Returns
* Risks To Realisation Of Return
* Market Summary
* Regulatory Regime
* Clinical Research
* Wholesale Sector
* Pharmacy Sector
* Parallel Imports
* Medical Devices
* Industry Forecast Scenario
* Overall Market Forecast
* Top Ten Generic Drugs By Value In 2008
* Competitive Landscape
* Company Profiles

Companies Mentioned:

* Hovione
* Bial
* Medinfar

For more information visit
http://www.researchandmarkets.com/research/bf05b8/portugal_pharmaceu

Laura Wood
Senior Manager
press@researchandmarkets.com
Fax from USA: 646-607-1907
Fax from rest of the world: +353-1-481-1716

Copyright Business Wire 2009